Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-based therapy for mantle cell lymphoma.

Corey M Munger1, Julie M Vose, Shantaram S Joshi

  • 1Department of Genetics, University of Nebraska Medical Center, Omaha, NE 68198-6395, USA.

International Journal of Oncology
|May 11, 2006
PubMed
Summary

This study shows that dendritic cell (DC)-Mantle cell lymphoma (MCL) hybrid immunotherapy effectively eliminates residual MCL cells. This approach significantly improves survival in preclinical models, offering a promising strategy for treating this B cell malignancy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteome landscape of B-cell malignancies identifies mantle cell lymphoma protein signature.

bioRxiv : the preprint server for biology·2026
Same author

Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

Blood advances·2026
Same author

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial.

Annals of hematology·2026
Same author

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Blood advances·2026
Same author

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.

Nature communications·2025
Same author

Cooperative role of distinctive TP53 and PTEN combined loss in the peripheral T cell lymphoma-GATA3 molecular subgroup.

Science advances·2025

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Mantle cell lymphoma (MCL) is a B cell malignancy often resistant to conventional therapies.
  • High-dose therapy (HDT) with stem cell transplantation induces remission but relapse due to residual lymphoma cells remains a challenge.
  • Novel therapeutic strategies are needed to eradicate residual MCL and prevent relapse.

Purpose of the Study:

  • To investigate the anti-lymphoma effects of cytotoxic T lymphocytes (CTLs) generated using dendritic cells (DCs) fused with MCL cells.
  • To evaluate the in vitro and in vivo efficacy of this DC-based immunotherapy against MCL.

Main Methods:

  • Dendritic cells (DCs) were generated and characterized.
  • DCs were fused with MCL cells to create DC-MCL hybrids.

Related Experiment Videos

  • DC-MCL hybrids were used to stimulate MCL-specific CTLs.
  • In vitro cytotoxicity assays were performed against MCL cell lines.
  • A preclinical mouse model (NOD-SCID mice with Granta 519 MCL tumors) was used to assess in vivo therapeutic effects.

    • Main Results:

    • Generated CTLs demonstrated specific cytotoxicity against the human MCL cell line GRANT-519 in vitro.
    • CTLs showed no significant effect against irrelevant cell targets.
    • In vivo treatment with DC-MCL hybrid-stimulated CTLs in mice led to a significant increase in survival (60% vs. 20% in untreated controls).
    • Histological analysis revealed a reduction in liver tumor nodules in the treatment group.

    Conclusions:

    • DC-MCL hybrid-stimulated CTLs exhibit potent MCL-specific anti-lymphoma activity.
    • This DC-based immunotherapy approach shows significant therapeutic potential in preclinical models of MCL.
    • Further investigation into DC-based therapy is warranted for treating mantle cell lymphoma.